Omega Diagnostics Group PLC Director/PDMR Shareholding and Total Voting Rights (1506U)

TIDMODX

RNS Number : 1506U

Omega Diagnostics Group PLC

31 March 2021

31 March 2021

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Director/PDMR Shareholding

Exercise of Options

and Total Voting Rights

Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has agreed to allot in total 300,000 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares"). This is following the exercise of share options under the Company's Third Unapproved Scheme by William Rhodes, Non-Executive Director of the Company, at a price of 15.25 pence per Ordinary Share.

Following this exercise, Mr. Rhodes has today sold all 300,000 Ordinary Shares at a price of 79.3086 pence per Ordinary Share. Following the above transactions Mr. Rhodes holds no Ordinary Shares but holds options over a further 1,080,406 Ordinary Shares.

Application will be made to the London Stock Exchange for the 300,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 9 April 2021.

Following Admission, the total number of Ordinary Shares in issue will be 182,569,796 and the total number of voting rights will therefore be 182,569,796. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.

Contacts:

 
 Omega Diagnostics Group PLC                      Tel: [phone] 
 Colin King, Chief Executive                www.omegadiagnostics.com 
 Kieron Harbinson, Group Finance Director 
 
 
 finnCap Ltd                                      Tel: [phone] 
 Geoff Nash / Teddy Whiley (Corporate 
  Finance) 
 Alice Lane (ECM) 
 
 Walbrook PR Limited                           Tel: [phone] or 
                                                [e-mail] 
 Paul McManus                                     Mob: [phone] 
 Lianne Cawthorne                                 Mob: [phone] 
 
 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
----  ------------------------------------------------------------------------------------------ 
 a.    Name                         William Rhodes 
                                   ------------------------------------------------------------- 
 2     Reason for notification 
      ---------------------------  ------------------------------------------------------------- 
 a.    Position/Status              Non-Executive Director 
      ---------------------------  ------------------------------------------------------------- 
 b.    Initial notification/        Initial Notification 
        Amendment 
      ---------------------------  ------------------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------------------------ 
 a.    Name                         Omega Diagnostics Group Plc 
      --------------------------- 
 b.    LEI                          2138007U9P4BTZTYIR92 
      ---------------------------  ------------------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
----  ------------------------------------------------------------------------------------------ 
 a.    Description of                Ordinary Shares of 4 pence each 
        the financial 
        instrument, type              ISIN: GB00B1VCP282 
        of instrument 
 
        Identification 
        Code 
      ---------------------------  ------------------------------------------------------------- 
 b.    Nature of the                Acquisition of Ordinary Shares following the 
        transaction                  Exercise of Share Options and Sale of Ordinary 
                                     Shares 
      ---------------------------  ------------------------------------------------------------- 
 
 c.    Price(s) and volume(s)              Price(s)        Volume(s) 
      ---------------------------         -------------- 
                                           15.25 p         300,000       Purchase 
                                          --------------  ------------ 
                                           79.3086p        300,000       Sale 
                                          --------------  ------------ 
 
 d.    Aggregated information       As above. 
        Aggregated Purchase 
        Volume 
        Aggregated Purchase 
        Price 
        Aggregated Sale 
        Volume 
        Aggregated Sale 
        Price 
      ---------------------------  ------------------------------------------------------------- 
 e.    Date of the transaction      31 March 2021 
      ---------------------------  ------------------------------------------------------------- 
 f.    Place of the transaction     London Stock Exchange 
      ---------------------------  ------------------------------------------------------------- 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHJBMBTMTTJBLB

(END) Dow Jones Newswires

March 31, 2021 07:31 ET (11:31 GMT)